Utibron Neohaler (Indacaterol/Glycopyrrolate) for COPD

Overview
Utibron Neohaler is a prescription drug approved by the Food and Drug Administration (FDA) as long-term maintenance treatment for airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Utibron Neohaler is a combination drug composed of Indacaterol and Glycopyrrolate.

Indacaterol is a long-acting beta-adrenoceptor agonist (LABA). Glycopyrrolate is an anticholinergic. Both drugs are long-acting bronchodilators. Both drugs are believed to work by relaxing and dilating the airways, making it easier to breathe.

How do I take it?
Utibron Neohaler is taken twice daily.

Utibron Neohaler comes in the form of powder capsules to be taken with the special Neohaler device.

Side effects
The FDA-approved label for Utibron Neohaler lists common side effects including cold symptoms and high blood pressure.

Rare but serious side effects listed for Utibron Neohaler can include paradoxical bronchospasm (bronchospasm caused by taking medication), worsening narrow-angle glaucoma or urinary retention, changes in blood glucose or electrolyte levels, and an increased risk for asthma-related death.

For more details about this treatment, visit:

Utibron – Novartis
http://www.utibron.com/index.jsp